Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance in Platinum-Sensitive Relapsed Ovarian Cancer
NCT03534453Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 45 months. Started May 2018; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03534453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534453.